This website has been developed and funded by Amicus Therapeutics® and is intended for healthcare professionals in GB (England, Scotland and Wales). If you are a member of the public click here. If you have been prescribed Pombiliti® + Opfolda® click here for the patient site.

Pompe HCP

Homepage

Move forward together

Introducing Pombiliti® + Opfolda®, the first and only two-component therapy for adults with Pompe disease, designed to address key challenges in delivering and maximising enzyme activity.1-3

Click here to access support resources for your patients

Always consult the full SmPC and risk management materials before prescribing and administering Pombiliti + Opfolda.

Prescribing information can be found at the top of this page.

PP-AT-GB-0002-0824 | August 2024
References
  1. Pombiliti® 105 mg powder for concentrate for solution for infusion. Summary of Product Characteristics.
  2. Opfolda® 65 mg hard capsules. Summary of Product Characteristics.
  3. Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20(12):1027-1037. doi:10.1016/S1474-4422(21)00331-8.